Anavex Life Sciences Corporation (AVXL) Options

I guess they are frustrated over being so consistently proven wrong for years now.

Like years ago when Missling bought a series of 375 $AVXL shares - what the heck was that about.

SSRIs May Speed Up Cognitive Decline

https://neurosciencenews.com/ssris-cognitive-decline-28439/

Good luck and GOD bless,

https://fintel.io/so/us/avxl Those Fintel numbers 40.83% Tute owned are 12/31/2024 numbers. That 40% is up 10% from what it was end of 3rd qtr 9/30/2024. Since end ofr 4th qtr we have had at least 30 trade days. Think most days the MOO and MOC orders are on the order of 100,000 shares. Today 120,000 MOC order. Total is something on the order of 3M shares. May 15tth you will find out what the tute totals were for 1st qtr of 2025. I find it interesting the average prices these tutes
have in their investment in Anavex stock. Anything from $14 pps Finally after you get to about tute #110 your down to those with average PPS of $7.00. NORTHERN TRUST CORP total shares 706,901 added during Q4 10,938 First buy Q4 2015 $4.90
TWO SIGMA ADVISERS, LP total shares 490,600 first buy Q1 2022 avg 4.45
And finally one who has the lowest pps.
HIKARI POWER LTD total shares 85,585 first buy Q4 2018 avg pps 2.72
Hikari Power LTD is based out of Tokyo. Their last reported 13F filing for Q4 2024 included $1,157,742,000 in managed 13F securities and a top 10 holdings concentration of 76.65%. Hikari Power LTD's largest holding is Berkshire Hathaway Inc Class A with shares held of 783. Whalewisdom has at least 46 13F filings.
BRK-A shares are $750,040.00 each I have some BRK-B shares They are only $500 a share.

John k9uwa

BAR123, there is a quid pro quo on Wall Street and it entails giving in to massive dilution and letting IBs repeatedly wet their beaks at your expense. In return, there is supposed to be IB support. That is not the way AVXL was born: it came about via reverse merger, gradual increase in share valuation, raising money at opportune times using an ATM facility. This way has actually been good for shareholders since 2014 when it started.

You are betting here on 2-73 for AD and on 3-71 for Schizophrenia right now. Of course, if the MAA fails then that will be very bad. You place your chips and you see what happens. Actually, this is one of my main complaints about the company since i first invested in it: I placed my bet on 2-73 succeeding with everything it was tried on and the company believed less in 2-73 than they purported to: their Rett and AD trials were too small because they got tyrannasaurus arms when it came to funding more patients in the trials. But, despite that, the MAA has a fighting chance and now they "get it" with respect to setting up the 3-71 P2 to be more stat sig. I think if you don't believe the MAA will succeed then YOUR risk management should involve selling now or at whatever price point you can achieve prior to the decision. Anavex does not have to hedge: it is going forward with its programs because that is what its life is all about.

You aren't selling because you also believe in the mission. And you are frustrated because, well, if SAVA could have a $2b market cap prior to its meltdown then why can't AVXL? Well, that is the way the cookie crumbles. Some day, the stock price will be inflated past what it is worth (as when it hit $30 several years ago.) Let's just wait and if things go the way we think they should, then we will be rewarded. All the frustration will slide away.

Not perturbed at all. But I think you have it flipped. I am the good guy. You crooks are the trolls.

I just find that kind of insider behavior performative and phony.

Good work, George. Your mere posting of a link to AVXL's website greatly perturbed one of the trolls. 

re: What you are requesting is just play acting, so of course you didn't get the response you wanted.[/I]

At $8/sh, considering their otherwise company related income. options, bennies etc,....a token 1000 shares would not take food off the table - AND shows that this is not just "a job" to them. These common stock investments are more flexible, liquid, no dividend restrictions. and reassure us that trial results are something they believe in and hope to benefit from upon approvals.[

You clearly do not understand how Missling operates.

https://fintel.io/so/us/avxl

Yea, it's going down. Nothing shocking about that - it's what it does best.

No, without confirmation $7.90's-$8 (double bottom) is not trustworthy.
As stated before, price will not have positive odds for upward until it confirms above the 4ema. Unless something happens in the next day or two the up angled 100period could not hold as support, thus increasing odds for more down while adding resistance. A sustained up move must positively stack the fast ema's. The resistance to upward movement is also increasing for now.

Given overshoots, your #'s are consistent with mine. Two different methods, same picture. Actually, if we add oldmystic charts then 3 methods yield same points of interest.

Green Trades

Hoskuld, just a quick response. The exec's to buy some nominal shares is to show confidence to us the retail holders. Nothing more nothing less. The "new exec" as I suggest would be president. Someone who could take Missling's place if they decide to go it alone and he wants to retire. Someone who Wall St. respects. If the company got bought out then this new President could run the new division for the big pharma. As it relates to the "no definitive rev foundation in place yet" , what pre rev bio has that? But many if not all with the data we have presented had their day in the sun and a huge run up. We haven't. Why? Maybe the answer is in your answer. Trial design issues, bullshit guidance, etc. MAA is our only hope right now. If we get hung up on the first stop for some strange reason we are in for some trouble. I doubt that would happen with all the data out there now but nothing surprises me with Dr. M. The thing that worries me the most is getting approval and then the street say but what about the revenue, lets see that first and they just kick the can down the road. I'm not too worried about that but that would be the Anavex way. In the back of my mind I still think it is because the company did not go public the old fashion way and are being punished. They did the same thing to DNDN back in the day. I am still long and strong and have not sold a dime. Just added along the way. Thanks for the response.

Thanks,Kentucky, I can see what you're describing. I have 7.80/7.50 as a target to consider. I find the Elliott Waves sometimes make a seventh wave to completion, so that might fit the forecast. In the longer time frame chart, the 8 dollar zone has been an important support level. It seems important as a target to respect . But as we know, AVXL gets butchered by wall street , so maybe best bargains can be found in the 7's. ... in this cycle. Who knows. 🫣

new test msg

BAR123, a couple of these execs, Missling included, get all their compensation and have nearly all their wealth from and in Anavex. No one expects someone with 95% of their wealth in Anavex to buy...more Anavex shares.

You want yet another executive that will report to CM? No thanks.

Shares go up and shares go down. We are actually lucky that Anavex shares do BOTH. Some pre-revenue biotech companies only see their shares go one way. Is $8 crazy? Nope. It will be crazy if 3-71 P2 readout is awesome. And it would be insane if MAA is approved. But, right now? Anything between $6-$26 is possible right now because there is no definitive revenue foundation in place yet.

If you are sincere and frustrated then you are not alone. I have a couple of real complaints too, most revolving around trial design and bulls**t schedule guidance (e.g., Rett trial restart, PD trial update by end of January, etc.) You can bet your bottom dollar that 3-71 will not read out in H1 - that was more puffery. But, the MAA workflow marches on, trials will end, new trials will start. I think we both have to put our frustrations away for now and just patiently wait for the material events that are coming.

I am 11 years long in this stock made some good money when we had that brief run up in 2021, but in the last 4 years I have to admit the haters the shorters and the Bashers have been 1000% correct about this stock. much more than the cheerleaders have been..... especially Captain cheerleader who is never right about anything

Hi Tom,J
I believe we are close to a bottom in the sector. Several indicators are showing positive divergences. Oversold on all time frames with possibility to overshoot on the down side. Weekly uptrend comes in around 7.5 and the fib retrace is at the same level. I can count five waves down so we could be done. I think we break the 8 range to break psychology. WDIK

Look at the graphic again. Note the estimated clock stops.
The timeline is roughly 11 months to get to CHMP opinion, depending on the clock stops. Given our EOY submission, we'll be hearing roughly late Nov, depending on our clock stops.

Ignore the "work days" silliness, folks.

The worst date would be the day the rejection is published. 💔

That’s the best “rant” I’ve read in quite some time. Keep them coming. I’ve had many of the same thoughts recently. I to have talked to IR. My experience is that there is no “team” just Clint and he’s unimpressive.

I take that back - the AH 1 share the other day was a premonition of today's $AVXL closing price.

Hope the dry powder dudes are at the ready to fire.

That 200 ma at 6.77 looks heading toward 7 dollars... and with another week or two of sliding and bleeding , AVXL could target this ma .
We have a "double bottom" now at 7.96.
(8 dollars). Past pivot Targets in the 7's, include a shoulder zone (7.40-6.80). 7.50 area, 7.25 area, 7.11/7.16 area. AVXL appears to show no upwave momentum right now. The bounce off 8 dollars peaked at 8.55 and tumbled right back down. Is 8 dollars a nice bargain? Do the large investors want to buy at 7 dollars? Price will go where they want it to go. Does today's "double bottom at 8" look trustworthy?

“The biggest issue I have with AVXL is that it has never received the respect it deserves.”

Wrong. Respect must be earned. Anavex has not earned respect.

The biggest issue I have with AVXL is that it has never received the respect it deserves Respect has to be earned, and this company hasn't earned it due to its poor execution. The CEO has lied repeatedly, hidden data, and delayed releases to suit his narrative. He lost whatever respect he had after the Rett Avatar AUC and the AD odds ratio. Additionally, he has surrounded himself with questionable employees who contribute nothing but are still paid very well.

Christopher U. Missling, PhD, MS, MBA, is the President and CEO of Anavex

https://www.anavex.com/about-us

GOD bless,

What you are requesting is just play acting, so of course you didn't get the response you wanted.

We are for the moment still a $8 stock thought, so smile now tomorrow may be worse.

Remember some people vehemently claimed at $15 that $AVXL would never drop below again.

The biggest issue I have with AVXL is that it has never received the respect it deserves. We saw one brief rise to $31 with no news, but despite having the best data in the industry, the stock didn’t move much. Every other CNS company that released decent news saw huge run-ups—every single one. Yes, they all eventually pulled back, but we never got that spike. Remember, even with the best data ever, no run. Why?

My theory is that Dr. Missling needs to be elevated to CEO, and a new president should be brought in. Why do you think we never got the run we deserve? Think back to when BIIB surged by $20 billion in market cap—we should have at least hit a $4 billion market cap. SAVA shot up to $120 per share, ANVS to $132, and AXSM to $130. Why not AVXL?

Who has the answer to this? I could accept a rise to $30 followed by a pullback to $20, but sitting here at $7.97 is crazy. Unless, of course, we’re not being believed, or maybe we’re being accumulated and the games are being played until we approach key milestones, like the first stop for Q&A, approval, or a partnership.

I understand that a buyback will never happen, and the executives won’t be purchasing shares—they never do. After most of them being on board for 5-10 years they have collected enough free shares. Just buy a little. All of them. But share purchases would signal to everyone that the company is in great shape and encourage patience. What do you think is behind the lack of a run-up for AVXL? Trust of Missling? Trouble with the data? No FDA love over the years?

Thanks in advance.

At an annual investor meeting I asked staff ( including IR guy if I remember right ) to show confidence in our drug results by purchasing some significant amount of AVXL shares to show they're putting some skin in the game. Most unenthusiastic responses followed.

What a disaster this POS has turned into. And I know it'll get worse. It ALWAYS does.

Lol! Do you by any chance have a worst expected date for approval or rejection?

CORRECTION>>>>>Anavex Life Sciences (AVXL) Institutional Ownership

https://www.marketbeat.com/stocks/NASDAQ/AVXL/institutional-ownership/

Good luck and GOD bless,

Sigma-1 agonists continue to exhibit positive effects in additional pathologies.
Are they the new Aspirin?

My best expectation is late July 2025 or early August 2025 for EMA approval of blarcamesine.

Good luck and GOD bless,

Anavex Life Sciences (AVXL) Institutional Ownership

https://link.springer.com/article/10.1007/s00210-025-03851-3

Good luck and GOD bless,

The graphic clearly shows the 120 day clock stop as four months.
So the 210 “working days” are calendar days.

So 30 weeks at an absolute minimum. 7.5 months that makes mid July.
However too optimistic for me so maybe October.

My best expectation is November.

Hoskuld--"None of that makes any sense"--good post and agree--TGD is running the co. the best he knows how---Monday morning Quarterbacks aren't going to change his mind---some shareholders may not like it but it is what it is--our day will come !!!

None of that makes any sense, BAR123. CM converts all his options to shares except those shares he needs to liquidate to cover transaction costs. Insider buys are NBD. And CM isn't going anywhere: 11 years of planning play out this year.

Short covering will happen when it happens. Generally that happens when material events make shorting unattractive. That is what we are all waiting for. Last year we sat around $4-$5 per share this year we sit at $8-$9 per share because MAA was filed and peer review was published and OLE results are good.

Buyback is not going to happen. The company sells shares regularly to keep capital on hand high enough to give them flexibility. They are not going to rebuy what they are selling

This is pre-revenue biotech: share are massively f***ed with until the game suddenly ends. That will happen soon.

And the press is out there screaming; fear, fear, fear! AVXL and the rest pay the price!

Jiong Ma is the Board Chair—I got confused with the president. Anyway, having a separate president won’t make a difference since he will still be the boss. However, since Ma joined, there have been visible changes in the company: A) new hires B) No new option grants to the clown since 2022—all his options were granted before that. Also, his most recent grant has milestones attached.

More of an "if the shoe fits..." for the dry powder crowd.

I am sure we will hear from the in @ 8.01 and out @ 8.45 yesterday seers!!!!

I thought Jiong Ma was the president of the company. There was a vote back in 2022/23 to separate responsibilities from TGD, but it looks like he is still the president. The Anavex website and 10-K filings still list him as president.

This company has become his personal playground. He operates with an iron fist, which is why Wall Street has no respect for him.

I do not day trade AVXL. I trade trading shares around a core position.
I do day trade a limited pool of select ETF's and among a few high volatility stocks.

Take a look at Tulsa
https://invst.ly/1950os

Would be nice to nail that trap door shut. 🤔. We shall see. Nice charts.

Next Monday Anavex Life Sciences’s will present at the 45th Annual TD Cowen Health Care Conference, March 3-5, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled at 9:50 AM (ET) on Monday, March 3rd, 2025, at the Boston Marriott Copley Place in Boston, MA.

A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. An archived edition of the session will be available later that day.

https://www.anavex.com/post/anavex-life-sciences-to-present-at-the-45th-annual-td-cowen-health-care-conference

Good luck and GOD bless,

oldmystic 02/07/25 8:42 AM
Post #482646 on Anavex Life Sciences Corp (AVXL)
A breakdown at 8.5 opens the door to 5.65: https://invst.ly/18t-mn
Axle Daily: https://invst.ly/1950dp